^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CMV/CD19 bi-Specific CAR T
i
Other names: CMV/CD19 bi-Specific CAR T, CMV-specific CD19-CAR T Cells, anti-CD19-CAR CMV-specific T-cells, Anti-CD19-CAR CMV-specific T-lymphocytes
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
City of Hope
Drug class:
CD19-targeted CAR-T immunotherapy, CMV-targeted CAR-T immunotherapy
Related drugs:
6d
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=15, Not yet recruiting, City of Hope Medical Center
New P1 trial • CAR T-Cell Therapy • Triplex vaccine
|
CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
10ms
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: Sep 2026 --> Mar 2028
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Triplex vaccine
|
CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
10ms
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2027 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Mar 2028
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
over1year
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy • Triplex vaccine
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
over1year
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=15, Not yet recruiting, City of Hope Medical Center
New P1 trial • CAR T-Cell Therapy • Triplex vaccine
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
2years
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
over2years
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=15, Not yet recruiting, City of Hope Medical Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2026
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
over2years
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=15, Not yet recruiting, City of Hope Medical Center
New P1 trial • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
Share via
